(19)

(11)

EP 4 132 964 A2

(12)

(88) Date of publication A3: 25.11.2021 (43) Date of publication: 15.02.2023 Bulletin 2023/07 (21) Application number: 21721753.8 (22) Date of filing: 06.04.2021

(51) International Patent Classification (IPC):  C07K 14/705(1995.01) A61K 38/00(1995.01) C12N 9/48(1980.01) A61P 31/14(2000.01) (52) Cooperative Patent Classification (CPC): C07K 14/70596; A61K 38/00; A61P 31/14; C12N 9/485; A61K 45/06 (86) International application number: PCT/US2021/025974 (87) International publication number: WO 2021/207207 (14.10.2021 Gazette 2021/41)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 07.04.2020 US 202063006463 P 21.05.2020 US 202063028401 P 13.06.2020 US 202062705150 P 22.07.2020 US 202063055051 P 03.08.2020 US 202063060489 P 20.10.2020 US 202063094179 P 03.02.2021 US 202163145352 P (71) Applicant: Neoleukin Therapeutics, Inc. Seattle, WA 98102 (US)

(72) Inventors: LINSKY, Thomas Seattle, Washington 98102 (US) SILVA MANZANO, Daniel Adriano Seattle, Washington 98102 (US) CODINA CASTILLO, Nuria Seattle, Washington 98102 (US) NELSON, Jorgen Seattle, Washington 98102 (US) WALKER, Matthew James Seattle, Washington 98102 (US) (74) Representative: Abel & Imray LLP  Westpoint Building James Street West Bath BA1 2DA Bath BA1 2DA (GB)